|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q56418529
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241121000051.0 |
|
008
|
|
|
241121nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q56418529
|
|
024
|
|
|
‡a
0000-0002-3561-1093
‡2
orcid
|
|
024
|
|
|
‡a
35299727500
‡2
scopus
|
|
035
|
|
|
‡a
(OCoLC)Q56418529
|
|
100
|
0 |
|
‡a
Liang-In Lin
‡9
ast
‡9
es
‡9
sl
|
|
400
|
0 |
|
‡a
Liang-In Lin
‡c
researcher
‡9
en
|
|
400
|
0 |
|
‡a
Liang-In Lin
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's Aberrant expression of annexin A10 is closely related to gastric phenotype in serrated pathway to colorectal carcinoma.
|
|
670
|
|
|
‡a
Author's AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.
|
|
670
|
|
|
‡a
Author's Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission
|
|
670
|
|
|
‡a
Author's Application of single nucleotide extension and MALDI-TOF mass spectrometry in proofreading and DNA repair assay
|
|
670
|
|
|
‡a
Author's BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer
|
|
670
|
|
|
‡a
Author's Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication
|
|
670
|
|
|
‡a
Author's Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
|
|
670
|
|
|
‡a
Author's Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
|
|
670
|
|
|
‡a
Author's Cytarabine-Resistant -ITD Leukemia Cells are Associated with Mutation and Multiple Pathway Alterations-Possible Therapeutic Efficacy of Cabozantinib
|
|
670
|
|
|
‡a
Author's Deciphering the Role of Pyrvinium Pamoate in the Generation of Integrated Stress Response and Modulation of Mitochondrial Function in Myeloid Leukemia Cells through Transcriptome Analysis
|
|
670
|
|
|
‡a
Author's Deoxyinosine repair in nuclear extracts of human cells.
|
|
670
|
|
|
‡a
Author's DNA polymerase I proofreading exonuclease activity is required for endonuclease V repair pathway both in vitro and in vivo
|
|
670
|
|
|
‡a
Author's Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia
|
|
670
|
|
|
‡a
Author's Frequent BRAF mutation in early-onset colorectal cancer in Taiwan: association with distinct clinicopathological and molecular features and poor clinical outcome
|
|
670
|
|
|
‡a
Author's Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
|
|
670
|
|
|
‡a
Author's Human parvovirus b19 infection in patients with coronary atherosclerosis.
|
|
670
|
|
|
‡a
Author's Human platelet antigen alleles in 998 Taiwanese blood donors determined by sequence-specific primer polymerase chain reaction
|
|
670
|
|
|
‡a
Author's Increased risk of parvovirus B19 infection in young adult cancer patients receiving multiple courses of chemotherapy
|
|
670
|
|
|
‡a
Author's Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
|
|
670
|
|
|
‡a
Author's KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells
|
|
670
|
|
|
‡a
Author's Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia.
|
|
670
|
|
|
‡a
Author's Marrow osteopontin level as a prognostic factor in acute myeloid leukaemia
|
|
670
|
|
|
‡a
Author's Overexpression of FLT3-ITD driven by spi-1 results in expanded myelopoiesis with leukemic phenotype in zebrafish.
|
|
670
|
|
|
‡a
Author's Overexpression of SOX4 correlates with poor prognosis of acute myeloid leukemia and is leukemogenic in zebrafish
|
|
670
|
|
|
‡a
Author's Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
|
|
670
|
|
|
‡a
Author's Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer
|
|
670
|
|
|
‡a
Author's Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
|
|
670
|
|
|
‡a
Author's Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway
|
|
670
|
|
|
‡a
Author's Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'.
|
|
670
|
|
|
‡a
Author's Resveratrol enhances the expression of death receptor Fas/CD95 and induces differentiation and apoptosis in anaplastic large-cell lymphoma cells.
|
|
670
|
|
|
‡a
Author's RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome
|
|
670
|
|
|
‡a
Author's Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information
|
|
670
|
|
|
‡a
Author's Suramin Inhibits Chikungunya Virus Entry and Transmission
|
|
670
|
|
|
‡a
Author's Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis.
|
|
670
|
|
|
‡a
Author's Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin
|
|
670
|
|
|
‡a
Author's Zebrafish as a disease model for studying human hepatocellular carcinoma
|
|
670
|
|
|
‡a
Author's Zebrafish as a Model for the Study of Human Myeloid Malignancies
|
|
909
|
|
|
‡a
(scopus) 35299727500
‡9
1
|
|
909
|
|
|
‡a
(orcid) 0000000235611093
‡9
1
|
|
919
|
|
|
‡a
frequentbrafmutationinearlyonsetcolorectalcancerintaiwanassociationwithdistinctclinicopathologicalandmolecularfeaturesandpoorclinicaloutcome
‡A
Frequent BRAF mutation in early-onset colorectal cancer in Taiwan: association with distinct clinicopathological and molecular features and poor clinical outcome
‡9
1
|
|
919
|
|
|
‡a
expressionofangiopoietinsandvascularendothelialgrowthfactorsandtheirclinicalsignificanceinacutemyeloidleukemia
‡A
Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia
‡9
1
|
|
919
|
|
|
‡a
dnapolymerase1proofreadingexonucleaseactivityisrequiredforendonuclease5repairpathwaybothinvitroandinvivo
‡A
DNA polymerase I proofreading exonuclease activity is required for endonuclease V repair pathway both in vitro and in vivo
‡9
1
|
|
919
|
|
|
‡a
deoxyinosinerepairinnuclearextractsofhumancells
‡A
Deoxyinosine repair in nuclear extracts of human cells.
‡9
1
|
|
919
|
|
|
‡a
decipheringtheroleofpyrviniumpamoateinthegenerationofintegratedstressresponseandmodulationofmitochondrialfunctioninmyeloidleukemiacellsthroughtranscriptomeanalysis
‡A
Deciphering the Role of Pyrvinium Pamoate in the Generation of Integrated Stress Response and Modulation of Mitochondrial Function in Myeloid Leukemia Cells through Transcriptome Analysis
‡9
1
|
|
919
|
|
|
‡a
cytarabineresistantitdleukemiacellsareassociatedwithmutationandmultiplepathwayalterationspossibletherapeuticefficacyofcabozantinib
‡A
Cytarabine-Resistant -ITD Leukemia Cells are Associated with Mutation and Multiple Pathway Alterations-Possible Therapeutic Efficacy of Cabozantinib
‡9
1
|
|
919
|
|
|
‡a
cycline1inhibitioncanovercomesorafenibresistanceinhepatocellularcarcinomacellsthrough11501suppression
‡A
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
‡9
1
|
|
919
|
|
|
‡a
cabozantinibisselectivelycytotoxicinacutemyeloidleukemiacellswithflt3internaltandemduplicationflt3itd
‡A
Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
‡9
1
|
|
919
|
|
|
‡a
aberrantexpressionofannexina10iscloselyrelatedtogastricphenotypeinserratedpathwaytocolorectalcarcinoma
‡A
Aberrant expression of annexin A10 is closely related to gastric phenotype in serrated pathway to colorectal carcinoma.
‡9
1
|
|
919
|
|
|
‡a
cabozantinibisselectivelycytotoxicinacutemyeloidleukemiacellswithflt3internaltandemduplication
‡A
Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication
‡9
1
|
|
919
|
|
|
‡a
brafmutationmayhavedifferentprognosticimplicationsinearlyandlatestagecolorectalcancer
‡A
BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer
‡9
1
|
|
919
|
|
|
‡a
applicationofsinglenucleotideextensionandmalditofmassspectrometryinproofreadinganddnarepairassay
‡A
Application of single nucleotide extension and MALDI-TOF mass spectrometry in proofreading and DNA repair assay
‡9
1
|
|
919
|
|
|
‡a
aml1runx1mutationsin470adultpatientswithdenovoacutemyeloidleukemiaprognosticimplicationandinteractionwithothergenealterations
‡A
AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.
‡9
1
|
|
919
|
|
|
‡a
antiviralactivitiesofniclosamideandnitazoxanideagainstchikungunyavirusentryandtransmission
‡A
Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission
‡9
1
|
|
919
|
|
|
‡a
zebrafishasadiseasemodelforstudyinghumanhepatocellularcarcinoma
‡A
Zebrafish as a disease model for studying human hepatocellular carcinoma
‡9
1
|
|
919
|
|
|
‡a
verticalblockadeoftheigfrpi3kaktmtorpathwayforthetreatmentofhepatocellularcarcinomatheroleofsurvivin
‡A
Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin
‡9
1
|
|
919
|
|
|
‡a
zebrafishasamodelforthestudyofhumanmyeloidmalignancies
‡A
Zebrafish as a Model for the Study of Human Myeloid Malignancies
‡9
1
|
|
919
|
|
|
‡a
traditionalserratedadenomahas2pathwaysofneoplasticprogressionthataredistinctfromthesessileserratedpathwayofcolorectalcarcinogenesis
‡A
Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis.
‡9
1
|
|
919
|
|
|
‡a
suramininhibitschikungunyavirusentryandtransmission
‡A
Suramin Inhibits Chikungunya Virus Entry and Transmission
‡9
1
|
|
919
|
|
|
‡a
sensitivemeasurementofquantitydynamicsofflt3internaltandemduplicationatearlytimepointsprovidesprognosticinformation
‡A
Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information
‡9
1
|
|
919
|
|
|
‡a
runx1genemutationinprimarymyelodysplasticsyndromethemutationcanbedetectedearlyatdiagnosisoracquiredduringdiseaseprogressionandisassociatedwithpooroutcome
‡A
RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome
‡9
1
|
|
919
|
|
|
‡a
resveratrolenhancestheexpressionofdeathreceptorfascd95andinducesdifferentiationandapoptosisinanaplasticlargecelllymphomacells
‡A
Resveratrol enhances the expression of death receptor Fas/CD95 and induces differentiation and apoptosis in anaplastic large-cell lymphoma cells.
‡9
1
|
|
919
|
|
|
‡a
replytoheterogeneitywithinamlwithcebpamutationsonlycebpadoublemutationsbutnotsinglecebpamutationsareassociatedwithfavorableprognosis
‡A
Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'.
‡9
1
|
|
919
|
|
|
‡a
potentiatingtheefficacyofmoleculartargetedtherapyforhepatocellularcarcinomabyinhibitingtheinsulinlikegrowthfactorpathway
‡A
Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway
‡9
1
|
|
919
|
|
|
‡a
potentialroleofcxcl13cxcr5signalinginimmunecheckpointinhibitortreatmentincancer
‡A
Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
‡9
1
|
|
919
|
|
|
‡a
oxaliplatinbasedchemotherapymightprovidelongerprogressionfreesurvivalinkrasmutantmetastaticcolorectalcancer
‡A
Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer
‡9
1
|
|
919
|
|
|
‡a
oxaliplatinbasedchemotherapyismorebeneficialinkrasmutantthaninkraswildtypemetastaticcolorectalcancerpatients
‡A
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients
‡9
1
|
|
919
|
|
|
‡a
overexpressionofsox4correlateswithpoorprognosisofacutemyeloidleukemiaandisleukemogenicinzebrafish
‡A
Overexpression of SOX4 correlates with poor prognosis of acute myeloid leukemia and is leukemogenic in zebrafish
‡9
1
|
|
919
|
|
|
‡a
overexpressionofflt3itddrivenbyspi1resultsinexpandedmyelopoiesiswithleukemicphenotypeinzebrafish
‡A
Overexpression of FLT3-ITD driven by spi-1 results in expanded myelopoiesis with leukemic phenotype in zebrafish.
‡9
1
|
|
919
|
|
|
‡a
marrowosteopontinlevelasaprognosticfactorinacutemyeloidleukaemia
‡A
Marrow osteopontin level as a prognostic factor in acute myeloid leukaemia
‡9
1
|
|
919
|
|
|
‡a
marrowangiogenesisassociatedfactorsasprognosticbiomarkersinpatientswithacutemyelogenousleukaemia
‡A
Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia.
‡9
1
|
|
919
|
|
|
‡a
krasmutationisapredictorofoxaliplatinsensitivityincoloncancercells
‡A
KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells
‡9
1
|
|
919
|
|
|
‡a
inductionofdnadamageinduciblegenegadd45betacontributestosorafenibinducedapoptosisinhepatocellularcarcinomacells
‡A
Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
‡9
1
|
|
919
|
|
|
‡a
increasedriskofparvovirusb19infectioninyoungadultcancerpatientsreceivingmultiplecoursesofchemotherapy
‡A
Increased risk of parvovirus B19 infection in young adult cancer patients receiving multiple courses of chemotherapy
‡9
1
|
|
919
|
|
|
‡a
humanplateletantigenallelesin998taiwaneseblooddonorsdeterminedbysequencespecific1polymerasechainreaction
‡A
Human platelet antigen alleles in 998 Taiwanese blood donors determined by sequence-specific primer polymerase chain reaction
‡9
1
|
|
919
|
|
|
‡a
humanparvovirusb19infectioninpatientswithcoronaryatherosclerosis
‡A
Human parvovirus b19 infection in patients with coronary atherosclerosis.
‡9
1
|
|
919
|
|
|
‡a
growtharrestdnadamageinduciblegene45gammaexpressionasaprognosticandpredictivebiomarkerinhepatocellularcarcinoma
‡A
Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
‡9
1
|
|
996
|
|
|
‡2
LC|nr 96024442
|
|
996
|
|
|
‡2
LC|n 82255859
|
|
996
|
|
|
‡2
BNF|15971168
|
|
996
|
|
|
‡2
CYT|AC000220713
|
|
996
|
|
|
‡2
CYT|AC000254740
|
|
996
|
|
|
‡2
CYT|AC000220711
|
|
996
|
|
|
‡2
J9U|987007350107705171
|
|
996
|
|
|
‡2
LC|n 85013292
|
|
996
|
|
|
‡2
CYT|AC000644438
|
|
996
|
|
|
‡2
CYT|AC000010161
|
|
996
|
|
|
‡2
SUDOC|267446977
|
|
996
|
|
|
‡2
CYT|AC000010163
|
|
996
|
|
|
‡2
ISNI|0000000082711930
|
|
996
|
|
|
‡2
CYT|AC000000531
|
|
996
|
|
|
‡2
LC|nr 92002957
|
|
996
|
|
|
‡2
SUDOC|190107332
|
|
996
|
|
|
‡2
CYT|AC000556981
|
|
996
|
|
|
‡2
ISNI|0000000396171797
|
|
996
|
|
|
‡2
DNB|1173619534
|
|
996
|
|
|
‡2
CAOONL|ncf10698873
|
|
996
|
|
|
‡2
ISNI|0000000081198012
|
|
996
|
|
|
‡2
ISNI|0000000080188103
|
|
996
|
|
|
‡2
CYT|AC000659829
|
|
996
|
|
|
‡2
CYT|AC000654199
|
|
996
|
|
|
‡2
CAOONL|ncf10696058
|
|
996
|
|
|
‡2
LC|nr 92033218
|
|
996
|
|
|
‡2
LC|no2020092165
|
|
996
|
|
|
‡2
LC|no2014058927
|
|
996
|
|
|
‡2
PLWABN|9810570821205606
|
|
996
|
|
|
‡2
LC|n 78041182
|
|
996
|
|
|
‡2
LC|n 88631995
|
|
996
|
|
|
‡2
LC|no2021128074
|
|
996
|
|
|
‡2
ISNI|0000000064222797
|
|
996
|
|
|
‡2
CYT|AC000614618
|
|
996
|
|
|
‡2
JPG|500125665
|
|
996
|
|
|
‡2
LC|n 81014018
|
|
996
|
|
|
‡2
CYT|AC000659631
|
|
996
|
|
|
‡2
LC|n 85295343
|
|
996
|
|
|
‡2
NII|DA0202915X
|
|
996
|
|
|
‡2
LC|n 91102635
|
|
996
|
|
|
‡2
CYT|AC000634851
|
|
996
|
|
|
‡2
CYT|AC000008755
|
|
996
|
|
|
‡2
LC|no2011182490
|
|
996
|
|
|
‡2
ISNI|0000000063393164
|
|
996
|
|
|
‡2
DNB|1155936019
|
|
996
|
|
|
‡2
NII|DA17303426
|
|
996
|
|
|
‡2
NUKAT|n 2013185296
|
|
996
|
|
|
‡2
CYT|AC000430412
|
|
996
|
|
|
‡2
CYT|AC000653954
|
|
996
|
|
|
‡2
ISNI|0000000063681457
|
|
996
|
|
|
‡2
ISNI|0000000064165788
|
|
996
|
|
|
‡2
BNF|17119203
|
|
996
|
|
|
‡2
DNB|1029270880
|
|
996
|
|
|
‡2
CYT|AC000008042
|
|
996
|
|
|
‡2
CYT|AC000662035
|
|
996
|
|
|
‡2
LC|n 81002137
|
|
996
|
|
|
‡2
KRNLK|KAC200605060
|
|
996
|
|
|
‡2
CYT|AC000633101
|
|
996
|
|
|
‡2
NII|DA11140271
|
|
996
|
|
|
‡2
CYT|AC000654023
|
|
996
|
|
|
‡2
CYT|AC000513433
|
|
996
|
|
|
‡2
ISNI|0000000084528988
|
|
996
|
|
|
‡2
CYT|AC000657883
|
|
996
|
|
|
‡2
NTA|142940100
|
|
996
|
|
|
‡2
J9U|987012502917805171
|
|
996
|
|
|
‡2
LC|n 88232001
|
|
996
|
|
|
‡2
BNF|15113495
|
|
996
|
|
|
‡2
DNB|1293626139
|
|
996
|
|
|
‡2
LC|n 2015066555
|
|
996
|
|
|
‡2
ISNI|0000000063316484
|
|
996
|
|
|
‡2
BIBSYS|90980928
|
|
996
|
|
|
‡2
LC|n 2016228226
|
|
996
|
|
|
‡2
NUKAT|n 2015005956
|
|
996
|
|
|
‡2
CYT|AC000352988
|
|
996
|
|
|
‡2
DNB|104741497X
|
|
996
|
|
|
‡2
SUDOC|266665233
|
|
996
|
|
|
‡2
NTA|227588584
|
|
996
|
|
|
‡2
LC|nr 90013037
|
|
996
|
|
|
‡2
DNB|173603343
|
|
996
|
|
|
‡2
ISNI|000000006433887X
|
|
996
|
|
|
‡2
LC|nr2006031427
|
|
996
|
|
|
‡2
ISNI|0000000064086537
|
|
996
|
|
|
‡2
ISNI|0000000083791127
|
|
996
|
|
|
‡2
CYT|AC000516821
|
|
996
|
|
|
‡2
LC|n 86002122
|
|
996
|
|
|
‡2
PLWABN|9812847711205606
|
|
996
|
|
|
‡2
CYT|AC000638173
|
|
996
|
|
|
‡2
LC|n 78017657
|
|
996
|
|
|
‡2
DNB|1342565282
|
|
996
|
|
|
‡2
PLWABN|9814000703205606
|
|
996
|
|
|
‡2
BNF|16793832
|
|
996
|
|
|
‡2
BNF|14479503
|
|
996
|
|
|
‡2
DNB|1263604617
|
|
996
|
|
|
‡2
SUDOC|138037337
|
|
996
|
|
|
‡2
ISNI|0000000080207087
|
|
996
|
|
|
‡2
CYT|AC000632122
|
|
996
|
|
|
‡2
RERO|A026463005
|
|
996
|
|
|
‡2
ISNI|0000000030396975
|
|
996
|
|
|
‡2
LC|n 81009924
|
|
996
|
|
|
‡2
BNF|17178473
|
|
996
|
|
|
‡2
DNB|1159176620
|
|
996
|
|
|
‡2
CYT|AC000652616
|
|
996
|
|
|
‡2
ISNI|0000000063409197
|
|
996
|
|
|
‡2
ISNI|0000000119642562
|
|
996
|
|
|
‡2
BIBSYS|8045794
|
|
996
|
|
|
‡2
DNB|1155109627
|
|
996
|
|
|
‡2
DNB|1209230402
|
|
996
|
|
|
‡2
ISNI|000000006341253X
|
|
996
|
|
|
‡2
CYT|AC000219734
|
|
996
|
|
|
‡2
DNB|108834657X
|
|
996
|
|
|
‡2
CYT|AC000219732
|
|
996
|
|
|
‡2
CAOONL|ncf11644974
|
|
996
|
|
|
‡2
DBC|87097968639190
|
|
996
|
|
|
‡2
CYT|AC000008089
|
|
996
|
|
|
‡2
DNB|173698077
|
|
996
|
|
|
‡2
LC|n 82015537
|
|
996
|
|
|
‡2
CYT|AC000508038
|
|
996
|
|
|
‡2
CYT|AC000008061
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
